Brentuximab vedotin for Stage III or IV Hodgkin's Lymphoma

Talal Hilal

doi:10.1056/NEJMc1802363

Brentuximab vedotin for Stage III or IV Hodgkin's Lymphoma

Hematology/Oncology

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1558-1559
Number of pages	2
Journal	New England Journal of Medicine
Volume	378
Issue number	16
DOIs	https://doi.org/10.1056/NEJMc1802363
State	Published - Apr 19 2018

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJMc1802363

Cite this

@article{3ca4616c032f4dcdba3121b8545c62b9,

title = "Brentuximab vedotin for Stage III or IV Hodgkin's Lymphoma",

author = "Talal Hilal",

year = "2018",

month = apr,

day = "19",

doi = "10.1056/NEJMc1802363",

language = "English (US)",

volume = "378",

pages = "1558--1559",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "16",

}

TY - JOUR

T1 - Brentuximab vedotin for Stage III or IV Hodgkin's Lymphoma

AU - Hilal, Talal

PY - 2018/4/19

Y1 - 2018/4/19

UR - https://www.scopus.com/pages/publications/85045871803

UR - https://www.scopus.com/inward/citedby.url?scp=85045871803&partnerID=8YFLogxK

U2 - 10.1056/NEJMc1802363

DO - 10.1056/NEJMc1802363

M3 - Letter

C2 - 29669231

AN - SCOPUS:85045871803

SN - 0028-4793

VL - 378

SP - 1558

EP - 1559

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 16

ER -

Brentuximab vedotin for Stage III or IV Hodgkin's Lymphoma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this